Ulla Peen

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Mansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J. Birrer et al. · The Lancet Oncology · 2019 · 239 citations

Superiority Trial, Medicine, Gynecology +8

Safety and dose modification for patients receiving niraparib

Jonathan S. Berek, Ursula A. Matulonis, Ulla Peen et al. · Annals of Oncology · 2018 · 183 citations

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Advanced Ovarian Cancer, Medicine, Pharmacology +9

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

Ignace Vergote, Bente Lund, Ulla Peen et al. · Gynecologic Oncology · 2019 · 46 citations

Oncology, Inhibitor Selinexor, Medicine +9

Mifepristone or vacuum aspiration in termination of early pregnancy

Jesper Legarth, Ulla Peen, J. Michelsen · European Journal of Obstetrics & Gynecology and Reproductive Biology · 1991 · 24 citations · Full text

Abortion, Gynecology, Maternal Health +6